A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderophore; or pharmaceutically acceptable salt or solvate thereof.

A composition for skin application and uses thereof are disclosed. The composition includes a sphingolipid containing a salicylic acid derivative as an active ingredient. The composition including a sphingolipid containing a salicylic acid derivative may exhibit, when applied to the scalp, an effect of alleviating scalp erythema, an effect of increasing the amount of moisture in the scalp, an effect of inhibiting scalp sebum secretion, an effect of inhibiting scalp itchiness, and the like.

A composition for skin application and uses thereof are disclosed. The composition includes a sphingolipid containing a salicylic acid derivative as an active ingredient. The composition including a sphingolipid containing a salicylic acid derivative may exhibit, when applied to the scalp, an effect of alleviating scalp erythema, an effect of increasing the amount of moisture in the scalp, an effect of inhibiting scalp sebum secretion, an effect of inhibiting scalp itchiness, and the like.

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.

The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.

The present invention relates to the design of novel molecules, referred to as multi-target molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the multi-target molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one multi-target molecule, and the use of such compositions in the treatment of cancer.

The present invention relates to the design of novel molecules, referred to as multi-target molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the multi-target molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one multi-target molecule, and the use of such compositions in the treatment of cancer.